Global Diabetes Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis, January 2013
A growing middle class population, changing demographic profile, increase in number of consumers with medical insurance, expanding economy, and increasing GDP per capita are expected to provide enormous opportunities for diabetes drug manufacturers in the Asia Pacific (APAC) region. The global industry experienced robust growth over the last five years and is expected to witness good growth by reaching approximately US $56.9 billion in 2018 with a CAGR of 6.5% over next five years.
Lucintel, a leading global management consulting and market research firm, has analyzed the global diabetes drugs industry and presents its findings in “Global Diabetes Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis.”
The diabetes drugs industry is highly consolidated with all classes of drugs used for the treatment of diabetes. North America dominates this industry, as the region is the largest consumer of diabetes drugs and represented 41.3% of the global diabetes drugs industry in 2012.
A combination of factors such as technology innovations, medical insurance coverage, rising income, aging population, and changing lifestyle greatly affect industry dynamics. The industry registered 10.9% growth in 2012 due to rapidly aging population and regulators’ efforts to increase healthcare access to its population. An expanding patient pool and changes in treatment patterns have resulted in growth for the diabetes drugs industry.
Lucintel’s research indicates that APAC holds good growth potential for the future as India is expected to play an important role in the global economy. Demand from a growing population continues to drive consumption for diabetes drugs. Major pharmaceuticals companies are planning to invest in the Asian markets to gain market share for diabetes drugs.
As per the study, there are several major drivers in the manufacturing area: growing per capita income and GDP with more government support, increasing diabetes cases, increased awareness, and changing demographics. The objective of all the strategies is discovery, manufacture, and commercialization of products that match the industry demands with regard to type, time, place, and price.
This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global diabetes drugs industry analysis. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.
Lucintel, a leading global management consulting and market research firm, has analyzed the global diabetes drugs industry and presents its findings in “Global Diabetes Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis.”
The diabetes drugs industry is highly consolidated with all classes of drugs used for the treatment of diabetes. North America dominates this industry, as the region is the largest consumer of diabetes drugs and represented 41.3% of the global diabetes drugs industry in 2012.
A combination of factors such as technology innovations, medical insurance coverage, rising income, aging population, and changing lifestyle greatly affect industry dynamics. The industry registered 10.9% growth in 2012 due to rapidly aging population and regulators’ efforts to increase healthcare access to its population. An expanding patient pool and changes in treatment patterns have resulted in growth for the diabetes drugs industry.
Lucintel’s research indicates that APAC holds good growth potential for the future as India is expected to play an important role in the global economy. Demand from a growing population continues to drive consumption for diabetes drugs. Major pharmaceuticals companies are planning to invest in the Asian markets to gain market share for diabetes drugs.
As per the study, there are several major drivers in the manufacturing area: growing per capita income and GDP with more government support, increasing diabetes cases, increased awareness, and changing demographics. The objective of all the strategies is discovery, manufacture, and commercialization of products that match the industry demands with regard to type, time, place, and price.
This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global diabetes drugs industry analysis. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.
1. EXECUTIVE SUMMARY
2. INDUSTRY DEFINITION AND SCOPE
3. INDUSTRY OVERVIEW
4. GLOBAL MACROECONOMIC OVERVIEW
5. INDUSTRY TRENDS
6. INDUSTRY FORECASTS
7. EMERGING TRENDS
8. CONCLUSIONS
2. INDUSTRY DEFINITION AND SCOPE
3. INDUSTRY OVERVIEW
4. GLOBAL MACROECONOMIC OVERVIEW
5. INDUSTRY TRENDS
6. INDUSTRY FORECASTS
7. EMERGING TRENDS
8. CONCLUSIONS
LIST OF FIGURES
Chapter 3. Industry Overview
Figure 3.1: External forces shaping global diabetes drugs industry
Chapter 4. Global Macroeconomic Overview
Figure 4.1: Global GDP growth rate trend
Figure 4.2: Global inflation rate trend
Figure 4.3: Global population growth rate trend
Figure 4.4: Global unemployment rate trend
Figure 4.5: Regional GDP growth rate trend
Figure 4.6: Regional inflation rate trend
Figure 4.7: Regional population growth rate trend
Figure 4.8: Regional unemployment rate trend
Chapter 5. Industry Trends
Figure 5.1: Global diabetes drugs industry annual trend 2007-12 (US $B)
Figure 5.2: Global diabetes drugs industry regional trend 2007-12 (US $B)
Figure 5.3: Global diabetes drugs industry regional trend 2007-12 (%)
Figure 5.4: Global diabetes drugs industry segment trend 2007-12 (US $B)
Figure 5.5: Global diabetes drugs industry segment trend 2007-12 (%)
Figure 5.6: Global diabetes drugs industry quarterly trend 2010-11 (US $B)
Figure 5.7: Global diabetes drugs industry profitability trend 2007-12
Figure 5.8: Global diabetes drugs industry revenue per employee Trend 2007-12
Figure 5.9: Cost structure of global diabetes drugs industry 2007-12
Figure 5.10: Cost structure in North American diabetes drugs industry 2007-12
Figure 5.11: Cost structure in European diabetes drugs industry 2007-12
Figure 5.12: Cost structure in Asia Pacific diabetes drugs industry 2007-12
Figure 5.13: Top 5 companies vs. diabetes drugs industry gross profit & net profit analysis 2012
Figure 5.14: Cash on hand for global diabetes drugs industry 2007-12 (US $B)
Figure 5.15: Cash on hand for global diabetes drugs industry 2007-12 (%)
Figure 5.16: Asset for global diabetes drugs industry 2007-12 (US $B)
Figure 5.17: Assets for global diabetes drugs industry 2007-12 (%)
Figure 5.18: Debt for global diabetes drugs industry 2007-12 (US $B)
Figure 5.19: Debt for global diabetes drugs industry 2007-12 (%)
Figure 5.20: Industry shares of top players in global diabetes drugs industry in 2007
Figure 5.21: Industry shares of top players in global diabetes drugs industry in 2012
Figure 5.22: Global diabetes drugs industry 2007 market share analysis
Figure 5.23: Global diabetes drugs industry 2012 market share analysis
Chapter 6. Industry Forecasts
Figure 6.1: Global diabetes drugs industry annual forecast 2013-18 (US $B)
Figure 6.2: Global diabetes drugs industry quarterly forecast 2013-14 (US $B)
Figure 6.3: Global GDP growth rate forecast
Figure 6.4: Global inflation rate forecast
Figure 6.5: Global population growth rate forecast
Figure 6.6: Global unemployment rate forecast
Figure 6.7: Regional GDP growth rate forecast
Figure 6.8: Regional inflation rate forecast
Figure 6.9: Regional population growth rate forecast
Figure 6.10: Regional unemployment rate forecast
Figure 6.11: Global diabetes drugs industry regional forecast 2013-18 (US $B)
Figure 6.12: Global diabetes drugs industry regional forecast 2013-18 (%)
Figure 6.13: Global diabetes drugs industry segment forecast 2013-18 (US $B)
Figure 6.14: Global diabetes drugs industry segment forecast 2013-18 (%)
Chapter 7. Emerging Trends
Figure 7.1: Global diabetes drugs industry opportunity by region
Figure 7.2: Global diabetes drugs industry opportunity by segment
Chapter 3. Industry Overview
Figure 3.1: External forces shaping global diabetes drugs industry
Chapter 4. Global Macroeconomic Overview
Figure 4.1: Global GDP growth rate trend
Figure 4.2: Global inflation rate trend
Figure 4.3: Global population growth rate trend
Figure 4.4: Global unemployment rate trend
Figure 4.5: Regional GDP growth rate trend
Figure 4.6: Regional inflation rate trend
Figure 4.7: Regional population growth rate trend
Figure 4.8: Regional unemployment rate trend
Chapter 5. Industry Trends
Figure 5.1: Global diabetes drugs industry annual trend 2007-12 (US $B)
Figure 5.2: Global diabetes drugs industry regional trend 2007-12 (US $B)
Figure 5.3: Global diabetes drugs industry regional trend 2007-12 (%)
Figure 5.4: Global diabetes drugs industry segment trend 2007-12 (US $B)
Figure 5.5: Global diabetes drugs industry segment trend 2007-12 (%)
Figure 5.6: Global diabetes drugs industry quarterly trend 2010-11 (US $B)
Figure 5.7: Global diabetes drugs industry profitability trend 2007-12
Figure 5.8: Global diabetes drugs industry revenue per employee Trend 2007-12
Figure 5.9: Cost structure of global diabetes drugs industry 2007-12
Figure 5.10: Cost structure in North American diabetes drugs industry 2007-12
Figure 5.11: Cost structure in European diabetes drugs industry 2007-12
Figure 5.12: Cost structure in Asia Pacific diabetes drugs industry 2007-12
Figure 5.13: Top 5 companies vs. diabetes drugs industry gross profit & net profit analysis 2012
Figure 5.14: Cash on hand for global diabetes drugs industry 2007-12 (US $B)
Figure 5.15: Cash on hand for global diabetes drugs industry 2007-12 (%)
Figure 5.16: Asset for global diabetes drugs industry 2007-12 (US $B)
Figure 5.17: Assets for global diabetes drugs industry 2007-12 (%)
Figure 5.18: Debt for global diabetes drugs industry 2007-12 (US $B)
Figure 5.19: Debt for global diabetes drugs industry 2007-12 (%)
Figure 5.20: Industry shares of top players in global diabetes drugs industry in 2007
Figure 5.21: Industry shares of top players in global diabetes drugs industry in 2012
Figure 5.22: Global diabetes drugs industry 2007 market share analysis
Figure 5.23: Global diabetes drugs industry 2012 market share analysis
Chapter 6. Industry Forecasts
Figure 6.1: Global diabetes drugs industry annual forecast 2013-18 (US $B)
Figure 6.2: Global diabetes drugs industry quarterly forecast 2013-14 (US $B)
Figure 6.3: Global GDP growth rate forecast
Figure 6.4: Global inflation rate forecast
Figure 6.5: Global population growth rate forecast
Figure 6.6: Global unemployment rate forecast
Figure 6.7: Regional GDP growth rate forecast
Figure 6.8: Regional inflation rate forecast
Figure 6.9: Regional population growth rate forecast
Figure 6.10: Regional unemployment rate forecast
Figure 6.11: Global diabetes drugs industry regional forecast 2013-18 (US $B)
Figure 6.12: Global diabetes drugs industry regional forecast 2013-18 (%)
Figure 6.13: Global diabetes drugs industry segment forecast 2013-18 (US $B)
Figure 6.14: Global diabetes drugs industry segment forecast 2013-18 (%)
Chapter 7. Emerging Trends
Figure 7.1: Global diabetes drugs industry opportunity by region
Figure 7.2: Global diabetes drugs industry opportunity by segment
LIST OF TABLES
Chapter 3. Industry Overview
Table 3.1: Industry parameters of global diabetes drugs industry
Table 3.2: Relative industry attractiveness by region
Chapter 5. Industry Trends
Table 5.1: Regional revenue growth rate
Table 5.2: Segment revenue growth rate
Table 5.3: Percentage change in cost structure
Table 5.4: Percentage change in cash on hand
Table 5.5: Percentage change in total asset
Table 5.6: Percentage change in total debt
Table 5.7: Key companies by revenue growth
Table 5.8: Key companies by revenue decline
Chapter 6. Industry Forecasts
Table 6.1: Global diabetes drugs regional forecast growth rate
Table 6.2: Global diabetes drugs segment forecast growth rate
Chapter 3. Industry Overview
Table 3.1: Industry parameters of global diabetes drugs industry
Table 3.2: Relative industry attractiveness by region
Chapter 5. Industry Trends
Table 5.1: Regional revenue growth rate
Table 5.2: Segment revenue growth rate
Table 5.3: Percentage change in cost structure
Table 5.4: Percentage change in cash on hand
Table 5.5: Percentage change in total asset
Table 5.6: Percentage change in total debt
Table 5.7: Key companies by revenue growth
Table 5.8: Key companies by revenue decline
Chapter 6. Industry Forecasts
Table 6.1: Global diabetes drugs regional forecast growth rate
Table 6.2: Global diabetes drugs segment forecast growth rate
